title: Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity. CaptISM Study Group. Captopril Insulin Sensitivity Multicenter Study Group.
abstract: Hypertension is often related to metabolic disorders, such as android obesity, glucose intolerance, dyslipidemia, and hyperinsulinism (X syndrome). Insulin resistance (IR), described as the common link among these disorders, could contribute to an increase in coronary risk. The euglycemic insulin clamp technique has been used to show that different classes of antihypertensive agents have different effects on IR. The purpose of this multicenter study was to compare the effects of captopril to those of nicardipine on insulin profile using the oral glucose tolerance test (OGTT), a routine-feasible test. After a 1-month single-blind placebo period, 154 patients with hypertension and android obesity were randomized to 3 months of double-blind therapy with either 50 mg captopril twice daily (n = 77) or 50 mg nicardipine twice daily n = 77). An OGTT with an assay of insulin was performed before and after active treatment. Lipid parameters, Factor VII (F VII), fibrinogen, plasminogen activator inhibitor 1 (PAI-1), and insulin-like growth factor I (IGF-I) were measured at the same time. After 3 months of treatment, the changes from baseline in mean +/- SD values for the insulin area under the curve (AUC) were -24.8 +/- 107.4 microIU x h/mL (-15.2%) for captopril v 6.1 +/- 98.6 microIU x h/mL (4.8%) for nicardipine (P = .072). Changes in peak insulin values were -18.3 +/- 86.2 microIU/mL (-14%) for captopril v 6.7 +/- 79.4 microIU/mL (6.6%) for nicardipine (P = .070).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hôpital de la Timone, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Raccah
authors.forename: M
authors.initials: M
authors.lastname: Pettenuzzo-Mollo
authors.forename: O
authors.initials: O
authors.lastname: Provendier
authors.forename: L
authors.initials: L
authors.lastname: Boucher
authors.forename: J A
authors.initials: JA
authors.lastname: Cozic
authors.forename: R
authors.initials: R
authors.lastname: Gorlier
authors.forename: P
authors.initials: P
authors.lastname: Huin
authors.forename: J
authors.initials: J
authors.lastname: Sicard
authors.forename: P
authors.initials: P
authors.lastname: Vague
mesh_terms: D000328:Adult; D000368:Aged; D000941:Antigens / Q000032:analysis*; D001794:Blood Pressure / Q000187:drug effects*; D002216:Captopril / Q000627:therapeutic use*; D004311:Double-Blind Method; D005167:Factor VII / Q000032:analysis*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000627:therapeutic use*; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D011863:Radioimmunoassay; D012307:Risk Factors
chemical_list: D000941:Antigens; D007328:Insulin; D008055:Lipids; C042580:factor VII clotting antigen; D005167:Factor VII; D005340:Fibrinogen; D002216:Captopril; D009529:Nicardipine